Even though further investigations are needed, especially at clinical level, these first experimental evidences highlight the functional role of the β3-AR subtype in melanoma malignancy, and suggest β3-AR as a therapeutically valid target to counteract melanoma progression. Here, ADRB3 is linked to melanoma.